ARWR vs CRL · rev $829.4M vs rev $2.00B
Arrowhead Pharmaceuticals Inc (ARWR) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
ARWR currently screens at market cap $10.59B. CRL currently screens at market cap $7.78B.
Not investment advice. Open the ARWR and CRL stock pages for the full models.
Not investment advice.